Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT ID: NCT07160608
Last Updated: 2026-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
75 participants
INTERVENTIONAL
2025-11-26
2028-02-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
NCT05162066
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
NCT01731561
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
NCT01363388
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
NCT00987389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tarperprumig Group 1
Participants will be administered tarperprumig dose regimen #1 or dose regimen #2.
Tarperprumig
Participants will receive tarperprumig.
Tarperprumig Group 2
Participants will be administered tarperprumig dose regimen #1 or dose regimen #2.
Placebo
Participants will receive placebo.
Tarperprumig
Participants will receive tarperprumig.
Placebo Group 3
Participants will be administered placebo.
Placebo
Participants will receive placebo.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Participants will receive placebo.
Tarperprumig
Participants will receive tarperprumig.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive test for antibodies to either PR3-ANCA or MPO-ANCA at Screening or in the past by a quantitative assay (for example, ELISA, bead assay).
* At least one major item, or at least 3 minor items, or at least 2 renal items in the BVAS.
Exclusion Criteria
* Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening.
* Any diseases or conditions that, in the judgment of the Investigator, present a substantial clinical risk to participate in this study.
* For patients with a previous diagnosis of CKD, patients known to have a stable eGFR for greater than 3 months prior to Screening and a decline less than 25% of previous eGFR at Screening will be excluded.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexion Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Leicester, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
La Plata, , Argentina
Research Site
Rosario, , Argentina
Research Site
San Juan Bautista, , Argentina
Research Site
Santa Fe, , Argentina
Research Site
Clayton, , Australia
Research Site
Heidelberg, , Australia
Research Site
Nedlands, , Australia
Research Site
Wollongong, , Australia
Research Site
Barretos, , Brazil
Research Site
Belo Horizonte, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Recife, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Etobicoke, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Baotou, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Guangzhou, , China
Research Site
Hangzhou, , China
Research Site
Nanchang, , China
Research Site
Shenzhen, , China
Research Site
Marseille, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Strasbourg, , France
Research Site
Toulouse, , France
Research Site
Berlin, , Germany
Research Site
Essen, , Germany
Research Site
Göttingen, , Germany
Research Site
Ludwigshafen, , Germany
Research Site
München, , Germany
Research Site
Brescia, , Italy
Research Site
Padua, , Italy
Research Site
Pavia, , Italy
Research Site
Pisa, , Italy
Research Site
Gdansk, , Poland
Research Site
Krakow, , Poland
Research Site
Poznan, , Poland
Research Site
Warsaw, , Poland
Research Site
Daegu, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daejeon, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Wŏnju, , South Korea
Research Site
Barcelona, , Spain
Research Site
Pamplona, , Spain
Research Site
San Sebastián de los Reyes, , Spain
Research Site
Santander, , Spain
Research Site
Seville, , Spain
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Altındağ, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Kocaeli, , Turkey (Türkiye)
Research Site
Merkez, , Turkey (Türkiye)
Research Site
Birmingham, , United Kingdom
Research Site
Cambridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521706-17-00
Identifier Type: OTHER
Identifier Source: secondary_id
ALXN1820-ANCA-201
Identifier Type: OTHER
Identifier Source: secondary_id
D6722C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.